...
search icon
agen-img

Agenus Inc Share Price

AGEN
NAQ
$3.355
-$0.02
(-0.59%)
1D
Industry: Biotechnology Sector: Health Care

Agenus Inc Analyst Forecast

Agenus Inc Share Price Chart

Agenus Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$121.80M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
86.62K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.67
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.38 L
$7.34 H
$3.355

About Agenus Inc, Common Stock

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. more

Industry: BiotechnologySector: Health Care

Agenus Inc Stock Returns

Time FrameAGENSectorS&P500
1-Week Return5.97%-2.29%-0.48%
1-Month Return9.77%-1.4%-2.16%
3-Month Return-17.6%0.66%-1.49%
6-Month Return-30.23%11.52%3.84%
1-Year Return56.74%3.71%20.8%
3-Year Return-88.55%23.36%75.57%
5-Year Return-94.57%34.74%73.91%
10-Year Return-95.36%127.63%240.27%

Agenus Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue88.17M295.67M98.02M156.31M103.46M[{"date":"2020-12-31","value":29.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":33.15,"profit":true},{"date":"2023-12-31","value":52.87,"profit":true},{"date":"2024-12-31","value":34.99,"profit":true}]
Cost of Revenue144.97M182.08M197.26M237.68M156.01M[{"date":"2020-12-31","value":60.99,"profit":true},{"date":"2021-12-31","value":76.61,"profit":true},{"date":"2022-12-31","value":82.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":65.64,"profit":true}]
Gross Profit(56.80M)113.59M(99.23M)(81.37M)(52.55M)[{"date":"2020-12-31","value":-50,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-87.36,"profit":false},{"date":"2023-12-31","value":-71.63,"profit":false},{"date":"2024-12-31","value":-46.26,"profit":false}]
Gross Margin(64.42%)38.42%(101.24%)(52.05%)(50.79%)[{"date":"2020-12-31","value":-167.67,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-263.51,"profit":false},{"date":"2023-12-31","value":-135.49,"profit":false},{"date":"2024-12-31","value":-132.21,"profit":false}]
Operating Expenses60.44M87.84M80.19M78.18M67.92M[{"date":"2020-12-31","value":68.81,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.29,"profit":true},{"date":"2023-12-31","value":89.01,"profit":true},{"date":"2024-12-31","value":77.33,"profit":true}]
Operating Income(117.23M)25.75M(179.43M)(159.55M)(120.47M)[{"date":"2020-12-31","value":-455.33,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-696.89,"profit":false},{"date":"2023-12-31","value":-619.68,"profit":false},{"date":"2024-12-31","value":-467.92,"profit":false}]
Total Non-Operating Income/Expense(126.73M)(120.19M)(113.09M)(168.96M)(229.42M)[{"date":"2020-12-31","value":-12673400000,"profit":false},{"date":"2021-12-31","value":-12019000000,"profit":false},{"date":"2022-12-31","value":-11309200000,"profit":false},{"date":"2023-12-31","value":-16895800000,"profit":false},{"date":"2024-12-31","value":-22942200000,"profit":false}]
Pre-Tax Income(182.89M)(28.72M)(230.66M)(257.44M)(232.27M)[{"date":"2020-12-31","value":-18289100000,"profit":false},{"date":"2021-12-31","value":-2872400000,"profit":false},{"date":"2022-12-31","value":-23065600000,"profit":false},{"date":"2023-12-31","value":-25743700000,"profit":false},{"date":"2024-12-31","value":-23227100000,"profit":false}]
Income Taxes57.24M65.97M40.86M(11.68M)-[{"date":"2020-12-31","value":86.77,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":61.93,"profit":true},{"date":"2023-12-31","value":-17.7,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(240.13M)(94.70M)(271.51M)(245.76M)-[{"date":"2020-12-31","value":-24013400000,"profit":false},{"date":"2021-12-31","value":-9469600000,"profit":false},{"date":"2022-12-31","value":-27151500000,"profit":false},{"date":"2023-12-31","value":-24576100000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(182.89M)(28.72M)(228.72M)(282.96M)(232.27M)[{"date":"2020-12-31","value":-18289100000,"profit":false},{"date":"2021-12-31","value":-2872400000,"profit":false},{"date":"2022-12-31","value":-22871900000,"profit":false},{"date":"2023-12-31","value":-28295700000,"profit":false},{"date":"2024-12-31","value":-23227100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(180.91M)(23.93M)(220.07M)(245.76M)(227.21M)[{"date":"2020-12-31","value":-18091400000,"profit":false},{"date":"2021-12-31","value":-2392600000,"profit":false},{"date":"2022-12-31","value":-22007400000,"profit":false},{"date":"2023-12-31","value":-24576100000,"profit":false},{"date":"2024-12-31","value":-22721200000,"profit":false}]
EPS (Diluted)(1.07)(0.21)(0.79)(0.71)(10.68)[{"date":"2020-12-31","value":-107,"profit":false},{"date":"2021-12-31","value":-21,"profit":false},{"date":"2022-12-31","value":-79,"profit":false},{"date":"2023-12-31","value":-71,"profit":false},{"date":"2024-12-31","value":-1068,"profit":false}]

Agenus Inc Ratios

Agenus Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

AGEN
Cash Ratio 0.01
Current Ratio 0.47

Agenus Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AGEN
ROA (LTM) -16.66%
ROE (LTM) -1278.83%

Agenus Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AGEN
Debt Ratio Lower is generally better. Negative is bad. 2.20
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.17

Agenus Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AGEN
Trailing PE NM
Forward PE 5.09
P/S (TTM) 1.07
P/B 218.61
Price/FCF NM
EV/R 1.39
EV/Ebitda 4.47
PEG 1.44

FAQs

What is Agenus Inc share price today?

Agenus Inc (AGEN) share price today is $3.355

Can Indians buy Agenus Inc shares?

Yes, Indians can buy shares of Agenus Inc (AGEN) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AGEN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Agenus Inc be purchased?

Yes, you can purchase fractional shares of Agenus Inc (AGEN) via the Vested app. You can start investing in Agenus Inc (AGEN) with a minimum investment of $1.

How to invest in Agenus Inc shares from India?

You can invest in shares of Agenus Inc (AGEN) via Vested in three simple steps:

  • Click on Sign Up or Invest in AGEN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Agenus Inc shares
What is Agenus Inc 52-week high and low stock price?

The 52-week high price of Agenus Inc (AGEN) is $7.34. The 52-week low price of Agenus Inc (AGEN) is $1.38.

What is Agenus Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Agenus Inc (AGEN) is

What is Agenus Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Agenus Inc (AGEN) is 218.61

What is Agenus Inc dividend yield?

The dividend yield of Agenus Inc (AGEN) is 0.00%

What is the Market Cap of Agenus Inc?

The market capitalization of Agenus Inc (AGEN) is $121.80M

What is Agenus Inc's stock symbol?

The stock symbol (or ticker) of Agenus Inc is AGEN

How Can Investors Use Agenus Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Agenus Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Agenus Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Agenus Inc shares for Indian investors?

When investing in Agenus Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Agenus Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Agenus Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Agenus Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Agenus Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top